ClinicalTrials.gg

Program

LV232

A development code. Also written as “LV232 40mg”, “LV232 60mg” and “LV232 20mg”.

Its studies are mostly in Depressive Disorder, Major, led by Vigonvita Life Sciences.

Furthest: phase 2, since Feb 10, 20254 company-led studies, 1 open or runningNext primary completion: Sep 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vigonvita Life Sciences41 open or runningphase 2since Feb 10, 2025Sep 30, 2023Sep 1, 2027phase 2 · NCT06828887

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 30, 2023First study: phase 1 study in Healthy SubjectsFirst studyNCT06070857 · 81 enrolled · China
  2. Jan 31, 2024Phase 1 study in Healthy SubjectsNCT06279533 · 49 enrolled · China
  3. Jun 18, 2024Phase 1 study in Depressive Disorder, MajorNCT06476509 · 20 enrolled · China
  4. Feb 10, 2025Phase 2 study in MDDNCT06828887 · 400 planned · China
  5. Oct 20, 2026Primary completion moved from 2026-09-01 to 2027-09-01Date moved laterphase 2 · +12 months · NCT06828887

Ahead

  1. Sep 1, 2027Primary completion: phase 2 study in MDDNCT06828887

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06828887MDD · China2RecruitingSep 1, 2027400
NCT06476509Depressive Disorder, Major · China1CompletedJan 19, 202520
NCT06279533Healthy Subjects · China1CompletedDec 17, 202449
NCT06070857Healthy Subjects · China1CompletedNov 17, 202581

How it is read

Names in the registry

  • “LV232 40mg”, 2 entries
  • “LV232 60mg”, 2 entries
  • “LV232”, 2 entries
  • “LV232 20mg”, 1 entry

Codes read as this program: LV232.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.